Skip to main content
HR 1496 110th Congress House Health Administrative procedure Antibiotics Biotechnology Clinical trials Commerce Communicable diseases Congressional reporting requirements Department of Health and Human Services Drug approvals Drug industry Drug resistance in microorganisms Executive reorganization Federal advisory bodies Food and Drug Administration (FDA) Government Operations and Politics Government paperwork Income tax Influenza Intellectual property

Beating Infections through Research and Development Act of 2007

Introduced: March 13, 2007 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 20, 2007
Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Mar 14, 2007
Referred to the Subcommittee on Health.
Mar 13, 2007
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 13, 2007
Introduced in House
 Plain-English summary Congressional Research Service

Beating Infections through Research and Development Act of 2007 - Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.

Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.

Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.

Establishes the Commission on Infectious Diseases Product Development to identify drug-resistant infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.

What's happening now April 20, 2007

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

 Committees of jurisdiction 5
 Cosponsors 1
All 1 Republican 1